Research Perspectives:

Real-world evidence to guide healthcare policies in oncology

Marco Donia _, Steen Werner Hansen and Inge Marie Svane _

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:4513-4515. https://doi.org/10.18632/oncotarget.27077

Metrics: PDF 1085 views  |   Full Text 1664 views  |   ?  


Marco Donia1, Steen Werner Hansen2 and Inge Marie Svane1

1 National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Herlev, Denmark

2 Head Office, Herlev and Gentofte Hospital, Herlev, Denmark

Correspondence to:

Marco Donia,email: [email protected]
Inge Marie Svane,email: [email protected]

Keywords: real-world evidence; real-world data; clinical trial eligibility

Received: June 02, 2019     Accepted: June 19, 2018     Published: July 16, 2019


Randomized controlled clinical trials (RCTs) in oncology enroll patients who meet strict protocol-specified criteria. Many of these criteria overlap across multiple RCTs. A vast proportion of patients with metastatic cancer do not meet such criteria. Hence, patient populations encountered in clinical practice are essentially different from RCT-populations, questioning the representativeness of these trials. A real-world evidence approach, using data from clinical practice, is increasingly employed to complement the information on drug safety and efficacy obtained from traditional clinical trials.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27077